abstract |
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ 42 lowering agent to a mammal under conditions in which levels of Aβ 42 are selectively reduced, levels of Aβ 38 are increased, and levels of Aβ 40 are unchanged. The invention provides methods and materials for developing and identifying Aβ 42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβ 42 lowering agents and antioxidants, Aβ 42 lowering agents and non-selective secretase inhibitors, as well as Aβ 42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ 42 lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ 42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors. |